

May 12, 2020

# Ono establishes a specified subsidiary and a local subsidiary in the US

Ono Pharmaceutical Co., Ltd (Head Office: Osaka City, President and Representative Director: Gyo Sagara; "ONO") announced today its resolution to establish a specified subsidiary, Ono Venture Investment Fund I, L.P. (the Fund), and a wholly-owned subsidiary, Ono Venture Investment, Inc. ("OVI") to manage the investment fund.

## 1. Aim of the establishments

For future access to innovative technologies/novel therapeutic drug targets and collaboration with early stage startup companies, OVI makes a strategic investment in such startup companies with cutting-edge technologies.

## 2. Summary of the specified subsidiary and the subsidiary

#### (Specified subsidiary: the Fund)

(eposition dubotatary, and raina)		
Name	Ono Venture Investment Fund I, L.P.	
Location	State of California, the US (planned)	
Purpose	Investment in startup companies	
Established	July 2020 (planned)	
Fund size	USD 100 million at maximum	
Investors	(1) Ono Pharmaceutical Co., Ltd (99%, planned)	
(Share)	(2) Ono Venture Investment, Inc. (1%, planned)	
Summary of	Name	Ono Venture Investment, Inc.
General	Location	State of California, the US (planned)
Partner	President/CEO	Hiroshi Yamamoto
	Main Business	Investment, financing, and management guidance in
	Activities	venture companies and their intermediation and referral
		(fund management).
	Capital	USD 2 million

# (The subsidiary: OVI)

	I	
Name	Ono Venture Investment, Inc.	
Location	State of California, the US (planned)	
Purpose	Investment, financing, and management guidance in venture companies	
	and their intermediation and referral (fund management).	
Established	May 12, 2020 (local time: planned)	
President/CEO	Hiroshi Yamamoto	
Capital	USD 2 million	
Relationship	A wholly-owned subsidiary of ONO	

## 3. Future Guidance.

We believe an impact of this incident on our company's financial results for the current fiscal year would be marginal, but any matter that may have a significant impact will be promptly disclosed in the future.

#### Contact:

Ono Pharmaceutical Co., Ltd. Corporate Communications <a href="mailto:public relations@ono.co.jp">public relations@ono.co.jp</a>